Feedback
Settings

Settings

Goto Application

358,666 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 35,867
1.WO/2026/098547ANTIBODY TARGETING CGRP AND USE THEREOF
WO - 15.05.2026
Int.Class C07K 16/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
26against hormones
 Appl.No PCT/CN2025/132978 Applicant HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. Inventor QIN, Lingyun
An antibody targeting CGRP and the use thereof. The antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises CDR-H1, CDR-H2 and CDR-H3. The light chain variable region comprises CDR-L1, CDR-L2 and CDR-L3. The antibody can specifically bind to human and rat CGRP polypeptides and α/β subtype CGRP polypeptides with high affinity, block the binding of CGRP to a receptor CGRPR thereof, reduce pain perception, and achieve the treatment of painful diseases such as migraines caused by CGRP. Additionally, the antibody can alleviate or treat hot flushes.
2.WO/2026/098577ANTI-CCR8 ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF, AND USE THEREOF
WO - 15.05.2026
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/CN2025/133127 Applicant GUANGDONG FAPON BIOPHARMA INC. Inventor GUO, Jian
The present application relates to the technical field of biology, and discloses an anti-CCR8 antibody or an antigen binding fragment thereof, and a use thereof. The antibody can specifically bind to at least one epitope of CCR8, can also bind to Treg cells, has ADCC activity, and provides new possibilities for the treatment and/or prevention of cancer.
3.WO/2026/102297ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE
WO - 15.05.2026
Int.Class A61K 31/7105
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
 Appl.No PCT/US2025/054619 Applicant STUART, William Inventor STUART, William
Disclosed herein are antibody-oligonucleotide conjugates, pharmaceutical compositions, and methods for treating Sickle Cell Disease. The disclosure contemplates compositions and methods capable of binding a human hematopoietic stem cell marker conjugated to an oligonucleotide capable of hybridizing a target sequence. In some embodiments, the target sequence is a BCL11A transcript sequence. In some embodiments of the disclosure, the antibody-oligonucleotide conjugate promotes antisense- and/or RNA interference-mediated inhibition of BCL11A.
4.WO/2026/102432HUMAN ANTIBODIES TO MARBURG VIRUS AND METHODS OF USE THEREFOR
WO - 15.05.2026
Int.Class C07K 16/10
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
08against material from viruses
10from RNA viruses
 Appl.No PCT/US2025/054898 Applicant VANDERBILT UNIVERSITY Inventor CROWE, JR., James E.
The present disclosure is directed to antibodies binding to and neutralizing Marburg Virus and methods for use thereof.
5.WO/2026/099807TYPE-I INTERFERON RESPONSE AND EXHAUSTION GENE SIGNATURE AS A BIOMARKER FOR CANCER IMMUNOTHERAPY
WO - 15.05.2026
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
 Appl.No PCT/IB2025/061397 Applicant UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor FERRIS, Robert, Louis
Provided herein is a method of treating a patient having a tumor, including determining whether one or more immune cells from the patient express an exhaustion phenotype and administering to the patient one or more therapeutic compositions, wherein: the therapeutic composition includes either one or more checkpoint inhibitors (ICIs) in an amount effective to treat the tumor when the one or more immune cells express the exhaustion phenotype or one or more compounds effective to prime the one or more immune cells to respond to one or more ICIs when the one or more cells do not express the exhaustion phenotype.
6.WO/2026/099867SUSTAINABLE ANTIFREEZE COATINGS BY PEPTIDE SELF-ASSEMBLY
WO - 15.05.2026
Int.Class C09D 5/16
CCHEMISTRY; METALLURGY
09DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
DCOATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
5Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects produced; Filling pastes
16Anti-fouling paints; Underwater paints
 Appl.No PCT/IL2025/051001 Applicant YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. Inventor RECHES, Meital
The technology disclosed in the application concerns antifreeze and anti-ice peptidic films.
7.WO/2026/101157BIOSENSOR SYSTEM FOR MONITORING EPOR DIMER FORMATION INDUCED BY LIGAND, AND TARGET LIGAND DETECTION METHOD USING SAME
WO - 15.05.2026
Int.Class G01N 33/74
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
74involving hormones
 Appl.No PCT/KR2025/017831 Applicant DAEGU GYEONGBUK INSTITUTE OF SCIENCE AND TECHNOLOGY Inventor LEE, Chang Hun
The present invention relates to a biosensor system for monitoring EPOR dimer formation by ligands and a target ligand detection method using same, wherein EPOR dimer formation by ligand binding can be rapidly and sensitively monitored using a fusion protein in which the EPOR ectodomain and a split fluorescent protein are fused. In addition, it is possible to monitor EPOR dimer formation by ligands and detect target ligands in vitro, and thus the complexity and duration of cell-based assays can be reduced, and high-speed screening can be easily applied. In addition, by measuring the reference fluorescence of a reference fluorescent protein together along with a signal fluorescence and comparing the reference fluorescence and signal fluorescence, accurate and quantitative analysis can be performed regardless of changes in measurement environment or variations in protein concentration.
8.WO/2026/101217COMPLEMENT C5-BINDING ANTAGONIST COMBINATION
WO - 15.05.2026
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
 Appl.No PCT/KR2025/018037 Applicant IMMUNABS INC. Inventor KIM, Dong Jo
The present invention relates to a novel complement C5-binding antagonist combination and a use thereof. The complement C5-binding antagonist combination according to the present invention comprises antagonists specifically binding to different domains of complement C5 and thus can significantly inhibit complement C5 activity, and therefore can be used for preventing or treating various complement-related diseases including myasthenia gravis, age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria.
9.WO/2026/097917BISPECIFIC ANTIBODY AGAINST TL1A AND IL-23 AND USE THEREOF
WO - 15.05.2026
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
 Appl.No PCT/CN2025/108267 Applicant BEIJING VDJBIO CO., LTD Inventor LI, Dongxia
Provided is a bispecific antibody, comprising: a first domain that specifically binds TNF-like ligand 1a (TL1A), and a second domain that specifically binds interleukin-23 (IL-23). Also provided is a method of using the bispecific antibodies for the treatment or prevention of diseases associated with TL1A and/or IL-23.
10.WO/2026/098007NANOBODY TARGETING IL-23A AND USE THEREOF
WO - 15.05.2026
Int.Class C07K 16/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
 Appl.No PCT/CN2025/116820 Applicant ZHANG, Fan Inventor ZHANG, Fan
The present invention belongs to the technical field of biomedicine. Provided are a nanobody targeting IL-23A and the use thereof. The nanobody comprises a framework region and a complementarity determining region, wherein the framework region comprises FR-H1, FR-H2, FR-H3 and FR-H4 having amino acid sequences as shown in SEQ ID NOs. 4-7, respectively; and the complementary determining region comprises CDR-H1, CDR-H2 and CDR-H3 having amino acid sequences as shown in SEQ ID NOs. 1-3, respectively. The nanobody can be used in the preparation of an antibody drug targeting IL-23A, which is capable of treating related diseases by means of binding to IL-23A.
# -